The present invention provides for dosing regimens for the treatment ofpatientswith cancer and/or an EFNA4-associated disorder with an anti-EFNA4 antibody-drugconjugate (ADC). The present invention further provides for methods for thetreatmentof patients with cancer and/or an EFNA4-associated disorder in which an anti-EFNA4ADC is administered intravenously weekly (QW) or every 3 weeks (Q3W).